Company profile ATRA

Atara Biotherapeutics Inc
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered fr...om cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have Show More
Quarter analysis & expected interestLast update: February 08 2024 15:36:52.

After 39 days of this quarter the interest is at 87.0. Based on that we can calculate that during remaining 52 days it will total up to 203.0.
Atara Biotherapeutics expected interest is significantly lower compared to previous quarter (-42.7%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019280
420
50.0% QoQ
757
80.2% QoQ
288
-62.0% QoQ
2020 429
53.2% YoY 49.0% QoQ
514
22.4% YoY 19.8% QoQ
276
-63.5% YoY -46.3% QoQ
256
-11.1% YoY -7.2% QoQ
2021 401
-6.5% YoY 56.6% QoQ
337
-34.4% YoY -16.0% QoQ
357
29.3% YoY 5.9% QoQ
345
34.8% YoY -3.4% QoQ
2022 269
-32.9% YoY -22.0% QoQ
420
24.6% YoY 56.1% QoQ
495
38.7% YoY 17.9% QoQ
348
0.9% YoY -29.7% QoQ
2023 274
1.9% YoY -21.3% QoQ
238
-43.3% YoY -13.1% QoQ
241
-51.3% YoY 1.3% QoQ
354
1.7% YoY 46.9% QoQ
2024 87
-68.2% YoY -75.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Atara Biotherapeutics search interestLast update: February 08 2024 15:36:51.
Correlation coefficient between keyword and revenue is 0.35
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:36:53.

The average 5 years interest of Atara Biotherapeutics was 28.3 per week.
The last year interest of Atara Biotherapeutics compared to the last 5 years has changed by -28.9%.
The interest for Atara Biotherapeutics is significantly decreasing.
The last year interest is quite lower compared to 5 years ago. It has decreased by -44.82%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tab-cel to provide analysis

Correlation between past revenue and Tab-cel search interest

There is not enough data for Tab-cel to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tab-cel to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 03 2023 20:28:06.

After 34 days of this quarter the interest is at 129.0. Based on that we can calculate that during remaining 58 days it will total up to 349.0.
T-cell immunotherapy expected interest is significantly higher compared to previous quarter (+206.1%) and same quarter last year (+336.2%).

YearQ1Q2Q3Q4
2018 - - - 42
2019 80
90.5% QoQ
31
-61.2% QoQ
60
93.5% QoQ
13
-69.0% YoY -78.3% QoQ
2020 79
-1.2% YoY 507.7% QoQ
23
-25.8% YoY -70.9% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2021 0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2022 12
inf% YoY inf% QoQ
137
inf% YoY 1041.7% QoQ
40
inf% YoY -70.8% QoQ
80
inf% YoY 100.0% QoQ
2023 100
733.3% YoY 25.0% QoQ
131
-4.4% YoY 31.0% QoQ
114
185.0% YoY -13.0% QoQ
129
61.2% YoY 13.2% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and T-cell immunotherapy search interestLast update: November 03 2023 20:28:06.
Correlation coefficient between keyword and revenue is 0.42
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 03 2023 20:28:07.

The average 5 years interest of T-cell immunotherapy was 4.1 per week.
The last year interest of T-cell immunotherapy compared to the last 5 years has changed by 141.95%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 141.95%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:36:57.

After 39 days of this quarter the interest is at 105.0. Based on that we can calculate that during remaining 52 days it will total up to 245.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201978
134
71.8% QoQ
158
17.9% QoQ
151
-4.4% QoQ
2020 160
105.1% YoY 6.0% QoQ
163
21.6% YoY 1.9% QoQ
169
7.0% YoY 3.7% QoQ
132
-12.6% YoY -21.9% QoQ
2021 148
-7.5% YoY 12.1% QoQ
177
8.6% YoY 19.6% QoQ
174
3.0% YoY -1.7% QoQ
176
33.3% YoY 1.1% QoQ
2022 451
204.7% YoY 156.2% QoQ
260
46.9% YoY -42.4% QoQ
238
36.8% YoY -8.5% QoQ
244
38.6% YoY 2.5% QoQ
2023 254
-43.7% YoY 4.1% QoQ
241
-7.3% YoY -5.1% QoQ
229
-3.8% YoY -5.0% QoQ
243
-0.4% YoY 6.1% QoQ
2024 105
-58.7% YoY -56.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Epstein-barr virus search interestLast update: February 08 2024 15:36:57.
Correlation coefficient between keyword and revenue is 0.13
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:36:59.

The average 5 years interest of Epstein-barr virus was 15.65 per week.
The last year interest of Epstein-barr virus compared to the last 5 years has changed by 18.34%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 66.85%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Post-transplant lymphoproliferative disease to provide analysis

Correlation between past revenue and Post-transplant lymphoproliferative disease search interest

There is not enough data for Post-transplant lymphoproliferative disease to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Post-transplant lymphoproliferative disease to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:37:03.

After 39 days of this quarter the interest is at 156.0. Based on that we can calculate that during remaining 52 days it will total up to 364.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019343
575
67.6% QoQ
515
-10.4% QoQ
454
-11.8% QoQ
2020 430
25.4% YoY -5.3% QoQ
420
-27.0% YoY -2.3% QoQ
535
3.9% YoY 27.4% QoQ
513
13.0% YoY -4.1% QoQ
2021 330
-23.3% YoY -35.7% QoQ
514
22.4% YoY 55.8% QoQ
472
-11.8% YoY -8.2% QoQ
274
-46.6% YoY -41.9% QoQ
2022 613
85.8% YoY 123.7% QoQ
478
-7.0% YoY -22.0% QoQ
501
6.1% YoY 4.8% QoQ
383
39.8% YoY -23.6% QoQ
2023 473
-22.8% YoY 23.5% QoQ
481
0.6% YoY 1.7% QoQ
541
8.0% YoY 12.5% QoQ
541
41.3% YoY 0.0% QoQ
2024 156
-67.0% YoY -71.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Nasopharyngeal carcinoma search interestLast update: February 08 2024 15:37:02.
Correlation coefficient between keyword and revenue is 0.1
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:37:04.

The average 5 years interest of Nasopharyngeal carcinoma was 36.56 per week.
The last year interest of Nasopharyngeal carcinoma compared to the last 5 years has changed by 3.72%.
The interest for Nasopharyngeal carcinoma is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by -5.93%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:37:09.

After 39 days of this quarter the interest is at 173.0. Based on that we can calculate that during remaining 52 days it will total up to 404.0.
CAR T immunotherapy expected interest is significantly higher compared to previous quarter (+82.8%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019268
261
-2.6% QoQ
180
-31.0% QoQ
259
43.9% QoQ
2020 415
54.9% YoY 60.2% QoQ
112
-57.1% YoY -73.0% QoQ
162
-10.0% YoY 44.6% QoQ
203
-21.6% YoY 25.3% QoQ
2021 191
-54.0% YoY -5.9% QoQ
267
138.4% YoY 39.8% QoQ
179
10.5% YoY -33.0% QoQ
163
-19.7% YoY -8.9% QoQ
2022 163
-14.7% YoY 0.0% QoQ
305
14.2% YoY 87.1% QoQ
191
6.7% YoY -37.4% QoQ
203
24.5% YoY 6.3% QoQ
2023 312
91.4% YoY 53.7% QoQ
282
-7.5% YoY -9.6% QoQ
315
64.9% YoY 11.7% QoQ
221
8.9% YoY -29.8% QoQ
2024 173
-44.6% YoY -21.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and CAR T immunotherapy search interestLast update: February 08 2024 15:37:08.
Correlation coefficient between keyword and revenue is 0.36
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:37:12.

The average 5 years interest of CAR T immunotherapy was 18.49 per week.
The last year interest of CAR T immunotherapy compared to the last 5 years has changed by 24.18%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 4.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:37:17.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Mesothelin expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
2019102
215
110.8% QoQ
263
22.3% QoQ
178
-32.3% QoQ
2020 140
37.3% YoY -21.3% QoQ
244
13.5% YoY 74.3% QoQ
130
-50.6% YoY -46.7% QoQ
168
-5.6% YoY 29.2% QoQ
2021 120
-14.3% YoY -28.6% QoQ
215
-11.9% YoY 79.2% QoQ
207
59.2% YoY -3.7% QoQ
167
-0.6% YoY -19.3% QoQ
2022 198
65.0% YoY 18.6% QoQ
249
15.8% YoY 25.8% QoQ
212
2.4% YoY -14.9% QoQ
89
-46.7% YoY -58.0% QoQ
2023 107
-46.0% YoY 20.2% QoQ
235
-5.6% YoY 119.6% QoQ
154
-27.4% YoY -34.5% QoQ
183
105.6% YoY 18.8% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Mesothelin search interestLast update: February 08 2024 15:37:17.
Correlation coefficient between keyword and revenue is 0.48
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:37:18.

The average 5 years interest of Mesothelin was 13.7 per week.
The last year interest of Mesothelin compared to the last 5 years has changed by -8.76%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -17.82%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for B-cell malignancies to provide analysis

Correlation between past revenue and B-cell malignancies search interest

There is not enough data for B-cell malignancies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for B-cell malignancies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 03 2023 20:29:04.

After 34 days of this quarter the interest is at 232.0. Based on that we can calculate that during remaining 58 days it will total up to 628.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 0
2019 0
0
0
0
2020 0
0
0
0
2021 0
0
0
0
2022 211
inf% YoY inf% QoQ
636
inf% YoY 201.4% QoQ
623
inf% YoY -2.0% QoQ
758
inf% YoY 21.7% QoQ
2023 658
211.8% YoY -13.2% QoQ
626
-1.6% YoY -4.9% QoQ
604
-3.0% YoY -3.5% QoQ
232
-69.4% YoY -61.6% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Multiple sclerosis search interestLast update: November 03 2023 20:29:04.
Correlation coefficient between keyword and revenue is 0.18
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 03 2023 20:29:04.

The average 5 years interest of Multiple sclerosis was 16.66 per week.
The last year interest of Multiple sclerosis compared to the last 5 years has changed by 199.4%.
This is something to be checked.
This didn't exist 5 years ago.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ATRA
Earnings date: 2024-02-27 After close
Company name: Atara Biotherapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T21:53:00-04:00

PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

2026-05-14T10:34:00-04:00

PR Newswire
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

2026-05-12T20:05:00Z

BusinessWire
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

2026-05-12T09:00:00-04:00

PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

2026-05-08T16:41:00-04:00

PR Newswire
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

2026-05-08T18:58:17Z

Analyst Upgrades
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

2026-05-07T10:00:00-04:00

PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

2026-05-07T12:05:00Z

BusinessWire
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

2026-05-07T01:08:00-04:00

PR Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

2026-05-06T09:40:00-04:00

PR Newswire
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

2026-05-05T15:33:00-04:00

PR Newswire
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

2026-05-05T09:00:00-04:00

PR Newswire
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA

2026-05-01T16:34:00-04:00

PR Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

2026-05-01T12:00:00-04:00

PR Newswire
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

2026-05-01T09:52:00-04:00

PR Newswire
ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026